Every dog has its day, and this week it was Blue Buffalo: the year's fifth-largest IPO surged over 30%. All three initial public offerings this week raised more capital than expected...read more
Neos Therapeutics, which is developing easily swallowed formulations of ADHD treatments, raised $72 million by offering 4.8 million shares (upsized from 4.0 million) at $15, the midpoint of the range of $14 to $16. Neos Therapeutics plans to list on the Nasdaq...read more
Fast-growing and highly-profitable pet food maker Blue Buffalo could be top dog this week. Five businesses and one blank check company are on the IPO calendar to raise over $1...read more
Neos Therapeutics, a late stage biotech developing extended release formulations of ADHD therapies, announced terms for its IPO on Monday. The Grand Prairie, TX-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14...read more
US IPO Weekly Recap: All natural pet food maker is top dog in a week with three IPOs
Every dog has its day, and this week it was Blue Buffalo: the year's fifth-largest IPO surged over 30%. All three initial public offerings this week raised more capital than expected...read more
Neos Therapeutics prices upsized IPO at the $15 midpoint
Neos Therapeutics, which is developing easily swallowed formulations of ADHD treatments, raised $72 million by offering 4.8 million shares (upsized from 4.0 million) at $15, the midpoint of the range of $14 to $16. Neos Therapeutics plans to list on the Nasdaq...read more
Week ahead: 5 IPOs during the week of July 20 are led by a Blue Buffalo
Fast-growing and highly-profitable pet food maker Blue Buffalo could be top dog this week. Five businesses and one blank check company are on the IPO calendar to raise over $1...read more
ADHD biotech Neos Therapeutics sets terms for $60 million IPO
Neos Therapeutics, a late stage biotech developing extended release formulations of ADHD therapies, announced terms for its IPO on Monday. The Grand Prairie, TX-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14...read more